Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications

  title={Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications},
  author={Russell Guy Ashley Jones and Angela Martino},
  journal={Critical Reviews in Biotechnology},
  pages={506 - 520}
  • R. JonesA. Martino
  • Published 20 January 2015
  • Medicine, Biology
  • Critical Reviews in Biotechnology
Abstract Therapeutic antibodies provide important tools in the “medicine chest” of today’s clinician for the treatment of a range of disorders. Typically monoclonal or polyclonal antibodies are administered in large doses, either directly or indirectly into the circulation, via a systemic route which is well suited for disseminated ailments. Diseases confined within a specific localized tissue, however, may be treated more effectively and at reduced cost by a delivery system which targets… 

Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections

The current state and future prospects of inhaled therapies, with an emphasis on the use of monoclonal antibodies for the treatment of respiratory infections, as well as an overview of their importance, practical challenges, and clinical trial outcomes are highlighted.

Application of Antibody-Mediated Therapy for Treatment and Prevention of Clostridium difficile Infection

The most promising orally administered drug candidate is a bovine antibody from hyperimmune colostral milk, which is in an advanced clinical development stage, and which antibody will enter the market is dependent on its bioavailability at the site of infection as well as its activity against C. difficile toxins.

Inflammatory bowel disease and targeted oral anti-TNFα therapy.

Ionic Liquids and Deep Eutectic Solvents for Enhanced Delivery of Antibodies in the Gastrointestinal Tract

In vivo results in rats demonstrate that CGLY effectively delivers TNFα antibody into the intestinal mucosa as well as systemic circulation, and illustrates the promise of using choline‐based ionic liquids and deep eutectic solvents as an oral delivery platform for local aswell as systemic delivery of therapeutic antibodies.

Potential Therapeutic Targets for Combination Antibody Therapy against Pseudomonas aeruginosa Infections

Despite advances in antimicrobial therapy and even the advent of some effective vaccines, Pseudomonas aeruginosa (P. aeruginosa) remains a significant cause of infectious disease, primarily due to

Review of local injection of anti-TNF for perianal fistulising Crohn’s disease

A potential role may be in those in whom systemic treatment is contraindicated and calls for standardised reporting of outcomes in this field to enable better data interpretation.

Pharmaco- and immunotherapeutic strategies for the topical treatment of cutaneous leishmaniasis

Thermosensitive hydrogels are of a great interest due to their many biomedical and pharmaceutical applications. In this study, we synthesized a new series of random poly (methyl vinyl ether-co-maleic



Progress in intra-articular therapy

Im intra-articular therapy is challenging because of the rapid egress of injected materials from the joint space; this elimination is true of both small molecules, which exit via synovial capillaries, and of macromolecules, which are cleared by the lymphatic system.

Local administration of monoclonal antibody-drug conjugate: a new strategy to reduce the local recurrence of colorectal cancer.

Findings indicate that local injection of immunoconjugate is a promising new field for controlling the local recurrence of colorectal cancer.

Passive antibody therapies: progress and continuing challenges.

Success in the development of antibody-based therapies will require extensive clinical research to learn how to use these compounds optimally and basic immunological research to define the basic mechanisms of antibody action.

Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye.

Based on its unique intraocular biodistribution and pharmacokinetics and the absolute intraocular levels reached, topical ESBA105 appears highly attractive for treatment of various ophthalmological disorders.

Therapeutic antibodies: successes, limitations and hopes for the future

An overview of the current state of the art of monoclonal antibodies is given and the most promising avenues that are being followed to create the next generation of antibody‐based therapeutic agents are described.

Ocular Distribution, Spectrum of Activity, and In Vivo Viral Neutralization of a Fully Humanized Anti-Herpes Simplex Virus IgG Fab Fragment following Topical Application

Topical instillation of an anti-HSV FAb fragment (AC-8) can be used on both intact and ulcerated corneas and is well tolerated and does not alter reepithelialization.

Antibody production: polyclonal-derived biotherapeutics.

Locally Delivered Polyclonal Antibodies Potentiate Intravenous Antibiotic Efficacy Against Gram-Negative Infections

Local delivery of human polyclonal antibodies to infection sites was shown to produce synergistic therapeutic efficacy in combination with systemic antibiotic administration in these lethal wound infection models in mice, providing antimicrobial efficacy independent of known pathogen resistance mechanisms.

AVX-470: A Novel Oral Anti-TNF Antibody with Therapeutic Potential in Inflammatory Bowel Disease

Oral administration of a surrogate antibody specific for mouse TNF is effective in treating mouse models of IBD, delivering the anti-TNF to the site of inflammation with minimal systemic exposure.